Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311752079> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W4311752079 abstract "Abstract Introduction COVID-19 pandemic still represents a major clinical problem worldwide. Many studies are actively being carried out to better understand prognostic factors of outcome as well as optimal treatment. Aim ACE-2 receptor is highly expressed on the surface of cardiac and pulmonary cells, and it is used by coronaviruses to enter host cells; this makes the role of ACE-inhibitors and Angiotensin Receptor Blockers (ARBs) drugs controversial. Moreover, it is still unclear whether these drugs may have any impact on sequelae. Methods In this retrospective study, we analysed a group of 244 hypertensive unvaccinated patients (134 on ACE-inhibitors, 110 on ARBs) admitted for moderate to severe COVID-19 pneumonia. As shown in the table, the two groups where homogeneous. Of these patients, 46 (20 treated with ACE-I and 26 treated with ARBs) came to a follow-up visit after a mean of 260 days; they underwent a quality-of-life assessment, laboratory and radiologic tests and spirometry (with DLCO). Results A total of 20 of 110 (18%) patients under treatment with ARBs and 23 of 134 (17%) died during hospitalization (p=0.8, NS). At discharge, biochemical, radiological and respiratory data were not significantly different. We did not find any significant difference in terms of radiologic alterations, lung fibrosis, spirometry data, DLCO, persisting effort dyspnea. Biochemical data were substantially super-imposable in the two groups. Conclusions we could not detect any difference in outcome nor in complications type or number in the two groups undergoing treatment with ACE-inhibitor or ARBs. This result seems to support and to strengthen the idea that ACE-inhibitors and ARBs do not play a significant role in onset, evolution and outcome of moderate to severe COVID-19 pneumoniae. Although the number of follow-up patients is small, we did not find any difference in follow-up sequelae in both groups." @default.
- W4311752079 created "2022-12-28" @default.
- W4311752079 creator A5000643094 @default.
- W4311752079 creator A5006375192 @default.
- W4311752079 creator A5015103908 @default.
- W4311752079 creator A5015301138 @default.
- W4311752079 creator A5017208564 @default.
- W4311752079 creator A5018144715 @default.
- W4311752079 creator A5020584719 @default.
- W4311752079 creator A5021404468 @default.
- W4311752079 creator A5023937066 @default.
- W4311752079 creator A5026010593 @default.
- W4311752079 creator A5027436936 @default.
- W4311752079 creator A5030244009 @default.
- W4311752079 creator A5034266039 @default.
- W4311752079 creator A5039632885 @default.
- W4311752079 creator A5042750799 @default.
- W4311752079 creator A5045058317 @default.
- W4311752079 creator A5056343925 @default.
- W4311752079 creator A5069910354 @default.
- W4311752079 creator A5071438185 @default.
- W4311752079 date "2022-12-14" @default.
- W4311752079 modified "2023-10-14" @default.
- W4311752079 title "1 ACE-INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS DO NOT IMPACT ON OUTCOME NOR IN LONG TERM CONSEQUENCES OF COVID-19" @default.
- W4311752079 doi "https://doi.org/10.1093/eurheartjsupp/suac121.383" @default.
- W4311752079 hasPublicationYear "2022" @default.
- W4311752079 type Work @default.
- W4311752079 citedByCount "0" @default.
- W4311752079 crossrefType "journal-article" @default.
- W4311752079 hasAuthorship W4311752079A5000643094 @default.
- W4311752079 hasAuthorship W4311752079A5006375192 @default.
- W4311752079 hasAuthorship W4311752079A5015103908 @default.
- W4311752079 hasAuthorship W4311752079A5015301138 @default.
- W4311752079 hasAuthorship W4311752079A5017208564 @default.
- W4311752079 hasAuthorship W4311752079A5018144715 @default.
- W4311752079 hasAuthorship W4311752079A5020584719 @default.
- W4311752079 hasAuthorship W4311752079A5021404468 @default.
- W4311752079 hasAuthorship W4311752079A5023937066 @default.
- W4311752079 hasAuthorship W4311752079A5026010593 @default.
- W4311752079 hasAuthorship W4311752079A5027436936 @default.
- W4311752079 hasAuthorship W4311752079A5030244009 @default.
- W4311752079 hasAuthorship W4311752079A5034266039 @default.
- W4311752079 hasAuthorship W4311752079A5039632885 @default.
- W4311752079 hasAuthorship W4311752079A5042750799 @default.
- W4311752079 hasAuthorship W4311752079A5045058317 @default.
- W4311752079 hasAuthorship W4311752079A5056343925 @default.
- W4311752079 hasAuthorship W4311752079A5069910354 @default.
- W4311752079 hasAuthorship W4311752079A5071438185 @default.
- W4311752079 hasBestOaLocation W43117520791 @default.
- W4311752079 hasConcept C126322002 @default.
- W4311752079 hasConcept C16020263 @default.
- W4311752079 hasConcept C164705383 @default.
- W4311752079 hasConcept C165637977 @default.
- W4311752079 hasConcept C27016395 @default.
- W4311752079 hasConcept C2776042228 @default.
- W4311752079 hasConcept C2777714996 @default.
- W4311752079 hasConcept C2777914695 @default.
- W4311752079 hasConcept C2779134260 @default.
- W4311752079 hasConcept C2779611605 @default.
- W4311752079 hasConcept C2780333948 @default.
- W4311752079 hasConcept C3008058167 @default.
- W4311752079 hasConcept C3018587741 @default.
- W4311752079 hasConcept C524204448 @default.
- W4311752079 hasConcept C71924100 @default.
- W4311752079 hasConcept C84393581 @default.
- W4311752079 hasConceptScore W4311752079C126322002 @default.
- W4311752079 hasConceptScore W4311752079C16020263 @default.
- W4311752079 hasConceptScore W4311752079C164705383 @default.
- W4311752079 hasConceptScore W4311752079C165637977 @default.
- W4311752079 hasConceptScore W4311752079C27016395 @default.
- W4311752079 hasConceptScore W4311752079C2776042228 @default.
- W4311752079 hasConceptScore W4311752079C2777714996 @default.
- W4311752079 hasConceptScore W4311752079C2777914695 @default.
- W4311752079 hasConceptScore W4311752079C2779134260 @default.
- W4311752079 hasConceptScore W4311752079C2779611605 @default.
- W4311752079 hasConceptScore W4311752079C2780333948 @default.
- W4311752079 hasConceptScore W4311752079C3008058167 @default.
- W4311752079 hasConceptScore W4311752079C3018587741 @default.
- W4311752079 hasConceptScore W4311752079C524204448 @default.
- W4311752079 hasConceptScore W4311752079C71924100 @default.
- W4311752079 hasConceptScore W4311752079C84393581 @default.
- W4311752079 hasIssue "Supplement_K" @default.
- W4311752079 hasLocation W43117520791 @default.
- W4311752079 hasOpenAccess W4311752079 @default.
- W4311752079 hasPrimaryLocation W43117520791 @default.
- W4311752079 hasRelatedWork W1966732677 @default.
- W4311752079 hasRelatedWork W1970948497 @default.
- W4311752079 hasRelatedWork W2016869337 @default.
- W4311752079 hasRelatedWork W2112752009 @default.
- W4311752079 hasRelatedWork W2127666157 @default.
- W4311752079 hasRelatedWork W2241164495 @default.
- W4311752079 hasRelatedWork W2260637182 @default.
- W4311752079 hasRelatedWork W2367778233 @default.
- W4311752079 hasRelatedWork W2467950981 @default.
- W4311752079 hasRelatedWork W2513596318 @default.
- W4311752079 hasVolume "24" @default.
- W4311752079 isParatext "false" @default.
- W4311752079 isRetracted "false" @default.
- W4311752079 workType "article" @default.